Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
A drug-fuelled mechanic who refused to accept his relationship with an ex-girlfriend was over bashed and repeatedly raped her during a nightmare kidnapping.
Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology
Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology
Potential for regional tuberculosis vaccines, novel personalized cancer vaccines, and improving checkpoint inhibition therapy
Helsinki, Finland, 19 April 2021: Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights for the proprietary ‘PeptiBAC’ technology from the University of Helsinki, Finland.
PeptiBAC uses the BCG (Bacillus Calmette-Guèrin) vaccine as a backbone for delivery of disease specific peptides. The technology has preventative potential in infectious diseases, specifically tuberculosis (TB, caused by Mycobacterium tuberculosis (MTB)), as well therapeutic potential in canc
Valo Therapeutics Acquires University of Helsinki s PeptiBAC Cancer and Infectious Disease Vaccination Technology
Potential for regional tuberculosis vaccines, novel personalized cancer vaccines, and improving checkpoint inhibition therapy
News provided by
Share this article
Share this article
HELSINKI, April 19, 2021 /PRNewswire/ Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights for the proprietary PeptiBAC technology from the University of Helsinki, Finland.
PeptiBAC uses the BCG (Bacillus Calmette-Guèrin) vaccine as a backbone for delivery of disease specific peptides. The technology has preventative potential in infectious diseases, specifically tuberculosis (TB, caused by Mycobacterium tuberculosis (MTB)), as well therapeutic potential in cancer. The BGC vaccine, one of the earliest immunotherapies, has been widely used globa